Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma in Situ, or Increased Breast Cancer Risk

NCT04570956 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04570956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04570956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma in Situ, or Increased Breast Cancer Risk
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
July 26, 2021
Completion date
October 15, 2024
Enrollment
65 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast atypical hyperplasia, breast atypical lobular hyperplasia, breast carcinoma, breast lobular carcinoma in situ